Welcome

The Biosimilars Working Group is a key collaboration of diverse non-profit organizations, registered health charities, and health care advocacy coalitions who are dedicated to ensuring that good outcomes for patients are at the centre of health policy in Canada, specifically in the biologic medication treatment areas.

We create up-to-date and evidence-based educational material for patients and health care professionals as a basis to inform our advocacy work on behalf of the patients who we serve.

To contact us, please email biosimilaroptions [at] gmail.com

Patient Experiences

Biosimilar Focus Group Report

This 2018 report focuses on the perspectives of Canadian patients with inflammatory diseases. Learn what they think about biologics, biosimilars, and the treatment decision process.

View the report on the Gastrointestinal Society’s website.

 

Biosimilars Survey Results

This survey from 2015 asked Canadian patients with inflammatory bowel disease to answer questions about patients opinions and understanding of biologics and biosimilars.

View the results on the Gastrointestinal Society’s website.

Patient Support Programs

Trying to manage insurance coverage, adherence, and biologic treatment goals can be daunting. Patient Support Programs are available in Canada to help patients navigate these tasks.

Learn more about Patient Support Programs.

Switching to a Biosimilar May Decrease Adherence

Learn more about the complications of switching patients from an originator biologic to a biosimilar. Our article and accompanying infographic explain how switching decreases retention rates.